SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Says Anthropic No Longer Seen as National Security Threat 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
